QURE - uniQure N.V.
IEX Last Trade
17.35
2.020 11.643%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:58 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$15.33
2.02
13.18%
Fundamental analysis
18%
Profitability
2%
Dept financing
18%
Liquidity
75%
Performance
20%
Performance
5 Days
2.18%
1 Month
189.65%
3 Months
259.96%
6 Months
289.01%
1 Year
174.53%
2 Year
-25.50%
Key data
Stock price
$17.35
DAY RANGE
$15.33 - $17.67
52 WEEK RANGE
$3.92 - $18.12
52 WEEK CHANGE
$155.15
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Matthew C. Kapusta
Region: US
Website: uniqure.com
Employees: 500
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: uniqure.com
Employees: 500
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
uniQure N.V. engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in clinical study for Huntington's disease.
Recent news